Reach Us +1-947-333-4405


C-kit, Erb2, EGFR And AKT Expression In Uterine Carcinosarcomas: An Exploratory Study | 3114
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1174

Journal of Clinical & Experimental Pathology received 1174 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

C-kit, Erb2, EGFR and AKT expression in uterine carcinosarcomas: An exploratory study

International Conference on Pathology

Ozlen Saglam, Seema Husain and Gokce Toruner

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.002

Uterine carcinosarcomas (UCS) result in ~15% of uterine cancer-associated deaths. C-kit, ERBB2, EGFR and AKT expressions were studied by immunohistochemistry, in order to evaluate their roles in the pathogenesis of UCS. In addition, exons 9 and 20 of PIK3CA gene, a critical gene in the AKT pathway, have been sequenced with ABI 3130xl Genetic Analyzer. The cohort (n=37) was composed of twenty-three early-stage (I and II) and fourteen late-stage (III and IV) tumors. The majority of carcinomatous components were pure serous adenocarcinoma (n=13). Fourteen cases showed heterologous elements in the sarcomatous components. An immunostaining score (IS) ranging from 0 to (6+) was calculated for C-kit, EGFR and AKT by adding the score of intensity and the percentage of positively stained cells. ASCO/CAP guidelines were used to evaluate ERBB2. AKT was positive in 35/37 cases with an IS ranging from (2+) to (5+). ERBB2 immunostain was (3+) in one case. EGFR was positive in 21/37 cases. Only six cases showed low IS with C-kit. AKT was expressed significantly more in the early-stage disease than late-stage disease (p=0.016). The sarcomatous component had a significantly higher IS than that of epithelial component (p=0.006). The expression of AKT in the epithelial component was associated with the survival (p=0.026). In one case, H1047R mutation on PIK3CA gene has been detected in both carcinomatous and sarcomatous components. These results indicate that AKT pathway is important in pathogenesis of UCS. Further studies with larger cohorts are warranted to confirm the observed associations in this study.

Ozlen Saglam has gained her M.D. degree from Marmara University, Istanbul, Turkey in 1992. She did AP/CP residency at Henry Ford Hospital, Detroit, MI. She has oncologic surgical pathology and cytopathology fellowships. Currently she is a member of women?s health group in the department of pathology at Yale University. Her areas of interest are breast and gynecologic pathology. She is serving as an editorial board member for the Journal of Clinical and Experimental Pathology.